TP53 overexpression and three-year survival in stage III and IV colorectal cancer: a retrospective cohort study

Nelsi Marintan Tampubolon; Ida Bagus Budhi Surya Adnyana; Prima Kharisma Hayuningrat; Suwardi; Henky Agung Nugroho; Pigur Agus Marwanto

doi:10.18203/2349-2902.isj20263334

Authors

Nelsi Marintan Tampubolon Faculty of Medicine, University of Sebelas Maret, DR Moewardi Hospital, Surakarta, Indonesia
Ida Bagus Budhi Surya Adnyana Digestive Surgery Division, Department of Surgery, Faculty of Medicine, University of Sebelas Maret, DR Moewardi Hospital, Surakarta, Indonesia
Prima Kharisma Hayuningrat Thorax and Cardiovascular Surgery Division, Department of Surgery, Faculty of Medicine, University of Sebelas Maret, DR Moewardi Hospital, Surakarta, Indonesia
Suwardi Pediatric Surgery Division, Department of Surgery, Faculty of Medicine, University of Sebelas Maret, DR Moewardi Hospital, Surakarta, Indonesia
Henky Agung Nugroho Oncology Surgery Division, Department of Surgery, Faculty of Medicine, University of Sebelas Maret, DR Moewardi Hospital, Surakarta, Indonesia
Pigur Agus Marwanto Faculty of Medicine, University of Sebelas Maret, DR Moewardi Hospital, Surakarta, Indonesia

DOI:

https://doi.org/10.18203/2349-2902.isj20263334

Keywords:

Colorectal cancer, TP53, p53 overexpression, Survival, Prognosis, Immunohistochemistry

Abstract

Background: TP53 mutations are among the most common molecular alterations in colorectal cancer (CRC) and are frequently associated with tumor aggressiveness and poor prognosis. This study evaluated the influence of TP53 overexpression on three-year overall survival in patients with stage III and IV CRC.

Methods: A retrospective cohort study was conducted on 46 patients with stage III–IV CRC treated at Dr. Moewardi General Hospital, Surakarta, Indonesia, between 2020 and 2023. TP53 expression was assessed using immunohistochemistry and categorized as overexpression or non-overexpression. Survival outcomes were analyzed using Chi-square and Kaplan–Meier methods with log-rank testing.

Results: Seventeen patients (36.9%) demonstrated TP53 overexpression, whereas 29 (63.1%) showed non-overexpression. Mortality before three years was significantly higher in the overexpression group (82.4%) than in the non-overexpression group (31.0%). TP53 overexpression was significantly associated with reduced three-year survival (p=0.001; Cramer’s V=0.495). Kaplan–Meier analysis demonstrated significantly shorter survival among patients with TP53 overexpression (log-rank p=0.002). Metastatic status and lymphovascular invasion were also associated with poorer survival.

Conclusions: TP53 overexpression is significantly associated with decreased three-year survival in advanced CRC and may serve as a useful prognostic biomarker for risk stratification and treatment planning.

References

Sung H, Filho AM, Laversanne M, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA Cancer J Clin. 2026;76(4).

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2024: Colorectal cancer burden worldwide. CA Cancer J Clin. 2024.

Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019;14(2):89-103.

Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol. 2011;6:479-507.

Nakayama M, Oshima M. Mutant p53 in colon cancer. J Mol Cell Biol. 2019 Apr 1;11(4):267-76.

Chen J. The cell-cycle arrest and apoptotic functions of p53 in tumor initiation and progression. Cold Spring Harb Perspect Med. 2016;6(3).

Donehower LA, Soussi T, Korkut A, Liu Y, Schultz A, Cardenas M, et al. Integrated analysis of TP53 gene and pathway alterations in The Cancer Genome Atlas. Cell Rep. 2019;28(5):1370-84.e5.

Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer. 2005;92(3):434-44.

Liebl MC, Hofmann TG. The role of p53 signaling in colorectal cancer. Cancers (Basel). 2021;13(9):2125.

Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer. 2005;92(3):434-44.

Li H, Zhang J, Tong JHM, Chan AWH, Yu J, Kang W, et al. Targeting the oncogenic p53 mutants in colorectal cancer and other solid tumors. Int J Mol Sci. 2019;20(23):5999.

Wang X, Sun Q. TP53 mutations, expression and interaction networks in human cancers. Oncotarget. 2017;8(1):624-43.

Solomon H, Dinowitz N, Pateras IS, Cooks T, Shetzer Y, Molchadsky A, et al. Mutant p53 gain of function underlies high expression levels of colorectal cancer stem cells markers. Oncogene. 2018;37(12):1669-84.

Gupta R, Bhatt LK, Johnston TP, Prabhavalkar KS. Colon cancer stem cells: potential target for the treatment of colorectal cancer. Cancer Biol Ther. 2019;20(8):1068-82.

Smeby J, Sveen A, Bergsland CH, Eilertsen IA, Danielsen SA, Eide PW, et al. Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer. ESMO Open. 2019;4(3).

Nakayama M, Hong CP, Oshima H, Sakai E, Kim SJ, Oshima M, et al. Loss of wild-type p53 promotes mutant p53-driven metastasis through acquisition of survival and tumor-initiating properties. Nat Commun. 2020;11:2333.

Argilés G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(10):1291-1305.

Betge J, Pollheimer MJ, Lindtner RA, Kornprat P, Schlemmer A, Rehak P, et al. Lymphovascular Invasion and Survival in Colorectal Cancer: A Systematic Review and Meta-analysis. PLoS One. 2012;7(9):e44568.

Michel M, Kaps L, Maderer A, Galle PR, Moehler M. The role of p53 dysfunction in colorectal cancer and its implication for therapy. Cancers (Basel). 2021;13(10):2296.

Hossain MS, Karuniawati H, Jairoun AA, Urbi Z, Ooi DJ, John A, et al. Colorectal cancer: a review of carcinogenesis, global epidemiology, current challenges, risk factors, preventive and treatment strategies. Cancers (Basel). 2022;14(7):1732.